Updated interim findings from a phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI demonstrate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results